VISION

We envision a future where patients are diagnosed earlier, empowered to monitor themselves, and treatment plans are optimized.

We aim to improve the lives of patients all over the world.

At GLX Analytix, we combine a new, proprietary class of biomarker with AI to bring personalized medicine to your healthcare.

The blood vessels of your body are lined with a natural fuzz.

Winner of
Roche Startup Award,
Future X Healthcare

“…this approach has a clear potential to improve the lives of patients all over the world”

— Head of Provider Insights, Information Soltuions, Tim M. Jaeger. Roche

Understanding the GLX principle

“Let me explain”

A quick guided intro to how it works and the potential of our approach.

Problem

The current lack of biomarkers for chronic illnesses leaves patients and their care-providers in the dark when it comes to diagnosis, treatment and monitoring.

A tool that monitors disease, and predicts attacks, would reduce side effects, improve clinical outcomes and quality of life and be pivotal for testing and approval of new drugs.

SOLUTION

We have discovered that an under-estimated and largely forgotten structure on the blood vessel wall, the glycocalyx, is cleaved off by immune cells in specific patterns before they invade the organ to cause harm. 

These patterns can be extracted and assembled from a blood sample, like a fingerprint for active disease.

We call this the GLX Signature

Example

In Multiple Sclerosis, a devastating disease attacking the brain, an individual experiences symptoms and receives an MRI.  They don’t know if they’ll have relapsing attacks, progress to a wheelchair, or even have no symptoms for the rest of their life. An MRI can only follow brain damage after damage has occurred, and is extremely expensive.

Solution

The discovery of the GLX Signature can help. In practice it’s a composite biomarker of inter-related components of the GLX. From these patterns, we build the GLX Signature.

Since our GLX Signature reflects early disease activity, before damage has occurred in the brain, it can be implemented as a monitoring system, both for patient attacks and treatment effect. In some respects, like a blood MRI.

By monitoring this signature, diagnosis improves, and most exciting: attacks can be predicted and treatments monitored in better detail, improving health, and keeping people out of the hospital.

Right treatment, right person, right time

Personalised medicine means not just shifting through the medicine of the day, but also facilitating the discovery, development and market approval of new and better interventions, with less side-effects.

The GLX Technology

The glx signature

Our proprietary technology plucks glycocalyx components out from the blood and reassembles the signal through machine learning, producing a GLX fingerprint we call the GLX Signature. 

Since the GLX is the first interaction between the blood and the rest of the body, the GLX Signature allows for early diagnosis, before damage has occured. The GLX Signature doubles as a tool for monitoring flares, treatment response and triples as a companion diagnostic for disease-modifying treatments, accelerating time-to-market through earlier and better patient recruitment, and proof-of-effect, a so-called ‘efficacy test’. 

1. Self monitoring

Blood sample

2. GLX Detection

Plucks glycocalyx components out

3. Machine learning

Reassembles the signal through machine learning

Partners

We are collaborating with clinicians across over 10 different chronic inflammatory diseases

We are currently collaborating with clinicians across over 10 different chronic inflammatory diseases ranging from autoimmune to psychiatric to neurodegenerative disorders. Contact us below for more information on our progress and how our platform can create value for you.  

We welcome you to be a part of the GLX family.

Contact

Brian Della Valle, PhD
CEO and Founder
Brian is a neuroscientist with a flare for new, exciting and groundbreaking ideas. He completed PhD in neuroscience with Novo Nordisk focusing on the neurotherapeutic effects of Victoza, the precusor to the blockbuster Ozempic. GLX ANALYTIX was born after a decade of cross talk with colleagues and a gradual eureka of sorts.
Richard Frank, MD, PhD
Chief Medical and Regulatory Officer (CMO/CRO)
Richard Frank is the Chief Medical and Regulatory Officer at GLX Analytix, former Chief Medical Officer of Siemens Healthineers, with 30 years of experience in regulatory labeling, public and private payment, and clinical adoption of therapeutic and diagnostic drugs and medical devices.
Maital Rasmussen
Chief Commercial Officer
Maital is a global leader in health technology commercialization, with over 20 years of experience in scaling businesses at Fortune 100 and startup companies, including roles at Octave Bioscience, Roche, Oracle, and JPMorgan, where she successfully launched precision medicine portfolios and drove revenue growth in healthcare technology.
Jerry Lanchbury, PhD
Scientific Advisor - Product Portfolio Management
Jerry Lanchbury is former Chief Scientific Officer of Myriad Genetics, recognized for leading groundbreaking innovations in molecular diagnostics across oncology, rheumatology, and cardiovascular diseases, including the development of transformative products like myChoice HRD, BracAnalysis CDx, and Vectra for cancer and autoimmune diseases.
Nancy Hargreaves
Chief Financial Officer
Nancy Hargreaves, bringing over 20 years of experience in financial strategy, fundraising, and operational excellence, having led major funding initiatives such as a $50M equity financing for Bridge to Life and a $30M Series B for Recros Medica, with a focus on guiding early-stage commercialization and high-growth companies in the MedTech and life sciences sectors.
Gisela Paulsen, MPharma
Commercial Advisor - Operations
Gisela has been at the forefront of early cancer detection for years, leading transformative efforts as President and COO at Oncocyte and at Exact Sciences, and now Harbinger Health. As Senior VP and Global Head of Clinical Operations at Roche, she led a 3,000-member global workforce, overseeing 400+ late-stage and post-approval clinical trials across 60 countries. Gisela has been recognized as PharmaVOICE's 100 Most Inspiring People in the Life Sciences Industry.
Mackenzie Strafford
Commercial Advisor - Reimbursement
Mackenzie is the Sr. Director of Strategy and Operations at Optum Health, where she leads major initiatives to drive performance and operational efficiency, including identifying over $200M in cost-saving measures. With a background at Bain & Company and Stop the Spread, she has extensive expertise in healthcare strategy, post-merger integration, and clinical decision support tools, and serves as an advisor for the Wyss Diagnostics Accelerator at Harvard University, where GLX Analytix is an inaugural member.
Dana Sun
Commercial Advisor - Investment Strategy
Dana is a Principal at Laerdal Million Lives Fund, where she invests in transformative medtech and health tech startups, with a focus on life-saving innovations and healthcare equity. Previously, at OCA Ventures, she led investments in digital health startups and at Genentech she identified $100M+ in commercial cost savings and assessed $250M+ in R&D investments for personalized healthcare, bringing extensive expertise in healthcare venture capital, strategic finance, and portfolio management.
Michele Colucci
Chair of the Board, VC Investor
Michele is the Chair of GLX Analytix and the Founder and CEO of Digital Dx Ventures, a Silicon Valley venture fund investing in the future of healthcare and the West Coast ambassador to the Nobel Laureate Foundation.
Mathias Lindh Jørgensen, PhD
Principal Specialist – Antibody Design, Production, and Innovation
Mathias specialises in antibody design, production and affinity maturation using phage display. He is leads our assay dev and is tasked with producing superior antibody products for the GLX portfolio.
Christoffer K. Goth, PhD
Principal Scientist – Operations and Innovation
Christoffer is a glycobiologst specialised in glycocalyx shedding and detection. Chris will lead our assay development with a focus on scalability and support our IP strategy.
Phillip Bredahl Mogensen, PhD
Senior Data Scientist
Phillip Mogensen is a Senior Data Scientist specializing in mathematical statistics and machine learning, with expertise in causal discovery and multiple testing procedures. Phillip is the architect of our GLXY2.0 AI system and currently serves as Data Platform Architect at VELUX.
Hjalte Bøgehave
Data Scientist
Hjalte was the architect of our GLXY1.0 AI platform for analyzing small-to mid-size datasets, and together with Phillip, co-architect of our new GLXY2.0, a "production-ready" AI pipeline for validation and commercialization.
Rikke Nielsen
Antibody Specialist
Rikke is a specialist in antibody design, phage display and affinity maturation and is tasked with bringing the strategy developed by Principal Scientist Mathias to life.
Charlotte Hybschmann Jacobsen
Investor
Charlotte’s collaborative nature as an investor supports our approach to tackling medicine’s biggest challenges.
Jørgen Rungby, PhD, MD
Clinical Advisor, Investor
Jørgen is our clinical advisor and bridges our lab work with clinic utility.